File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Electrophysiological effects of tocainide on canine subendocardial Purkinje fibers surviving infarction

TitleElectrophysiological effects of tocainide on canine subendocardial Purkinje fibers surviving infarction
Authors
Issue Date1986
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar
Citation
European Journal Of Pharmacology, 1986, v. 124 n. 1-2, p. 135-141 How to Cite?
AbstractThe effects of 10 and 20 mg/l of tocainide on transmembrane action potential characteristics were examined in Purkinje fibers surviving infarction. Infarcted tissue was obtained from canine hearts 24 h after coronary artery ligation. The preparation was stimulated at basic cycle lengths (BCL) of 1000-300 ms. Tocainide reduced the overshoot and amplitude of Purkinje fibers surviving infarction. The maximum upstroke velocity (V̇(max)) was decreased by tocainide in a dose dependent manner. This effect was more prominent at the shorter BCL. Statistical analysis revealed a significant interaction of the BCL with the drug effect on overshoot, amplitude, V̇(max) and action potential durations (APD50(%) and APD90(%)). Tocainide reduced the effective refractory period (ERP) at the BCL of 1000 ms, but had no significant effect at the BCL of 300 ms. Membrane responsiveness and steady state characteristics of V̇(max) were shifted significantly to more negative membrane potentials by tocainide. Investigation of the recovery kinetics of V̇(max) in the presence of tocainide showed an exponential recovery of V̇(max) with a time constant of 514 ms. These results support the finding that the effect of tocainide on V̇(max) and conduction is enhanced at faster rates of stimulation. Thus tocainide may be able to depress conduction to produce bidirectional block in the termination of ventricular tachycardia caused by reentry, while having minimal effect on conduction at normal heart rates.
Persistent Identifierhttp://hdl.handle.net/10722/170820
ISSN
2015 Impact Factor: 2.73
2015 SCImago Journal Rankings: 1.115
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKinnaird, AAAen_US
dc.contributor.authorMan, RYKen_US
dc.date.accessioned2012-10-30T06:11:00Z-
dc.date.available2012-10-30T06:11:00Z-
dc.date.issued1986en_US
dc.identifier.citationEuropean Journal Of Pharmacology, 1986, v. 124 n. 1-2, p. 135-141en_US
dc.identifier.issn0014-2999en_US
dc.identifier.urihttp://hdl.handle.net/10722/170820-
dc.description.abstractThe effects of 10 and 20 mg/l of tocainide on transmembrane action potential characteristics were examined in Purkinje fibers surviving infarction. Infarcted tissue was obtained from canine hearts 24 h after coronary artery ligation. The preparation was stimulated at basic cycle lengths (BCL) of 1000-300 ms. Tocainide reduced the overshoot and amplitude of Purkinje fibers surviving infarction. The maximum upstroke velocity (V̇(max)) was decreased by tocainide in a dose dependent manner. This effect was more prominent at the shorter BCL. Statistical analysis revealed a significant interaction of the BCL with the drug effect on overshoot, amplitude, V̇(max) and action potential durations (APD50(%) and APD90(%)). Tocainide reduced the effective refractory period (ERP) at the BCL of 1000 ms, but had no significant effect at the BCL of 300 ms. Membrane responsiveness and steady state characteristics of V̇(max) were shifted significantly to more negative membrane potentials by tocainide. Investigation of the recovery kinetics of V̇(max) in the presence of tocainide showed an exponential recovery of V̇(max) with a time constant of 514 ms. These results support the finding that the effect of tocainide on V̇(max) and conduction is enhanced at faster rates of stimulation. Thus tocainide may be able to depress conduction to produce bidirectional block in the termination of ventricular tachycardia caused by reentry, while having minimal effect on conduction at normal heart rates.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejpharen_US
dc.relation.ispartofEuropean Journal of Pharmacologyen_US
dc.subject.meshAction Potentials - Drug Effectsen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAnti-Arrhythmia Agents - Pharmacologyen_US
dc.subject.meshDogsen_US
dc.subject.meshElectric Stimulationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHeart - Innervationen_US
dc.subject.meshHeart Conduction System - Drug Effectsen_US
dc.subject.meshKineticsen_US
dc.subject.meshLidocaine - Analogs & Derivatives - Pharmacologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMyocardial Infarction - Physiopathologyen_US
dc.subject.meshPurkinje Fibers - Drug Effectsen_US
dc.subject.meshTocainideen_US
dc.titleElectrophysiological effects of tocainide on canine subendocardial Purkinje fibers surviving infarctionen_US
dc.typeArticleen_US
dc.identifier.emailMan, RYK:rykman@hkucc.hku.hken_US
dc.identifier.authorityMan, RYK=rp00236en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0014-2999(86)90133-0-
dc.identifier.pmid3087761-
dc.identifier.scopuseid_2-s2.0-0022606898en_US
dc.identifier.volume124en_US
dc.identifier.issue1-2en_US
dc.identifier.spage135en_US
dc.identifier.epage141en_US
dc.identifier.isiWOS:A1986C659400016-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridKinnaird, AAA=6603472891en_US
dc.identifier.scopusauthoridMan, RYK=7004986435en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats